Astria Therapeutics, Inc. (ATXS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Jill C. Milne Ph.D. | Co-Founder, CEO, President & Director | 967.34k | -- | 1968 |
| Mr. Benjamin S. Harshbarger J.D. | Chief Legal Officer | 658.04k | -- | 1969 |
| Dr. Christopher J. Morabito M.D. | Chief Medical Officer | 690.82k | -- | 1970 |
| Mr. Noah C. Clauser CPA | CFO & Treasurer | 621.41k | -- | 1974 |
| Ms. Keri McGrail | Chief Human Resources Officer | -- | -- | -- |
| Ms. Andrea L. Matthews | Chief Business Officer | -- | -- | 1982 |
| Mr. Andrew A. Komjathy | Chief Commercial Officer | -- | -- | 1963 |
| Mr. John Ruesch | Senior Vice President of Pharmaceutical Sciences & Technical Operations | -- | -- | -- |
| Ms. Rafif Dagher | Senior VP and Head of Discovery, Nonclinical Development & Translational Research | -- | -- | -- |
Astria Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 78
Description
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Corporate Governance
Upcoming Events
August 11, 2025 at 8:00 PM UTC - August 15, 2025 at 8:00 PM UTC
Astria Therapeutics, Inc. Earnings Date